睿智医药(300149) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥261,261,312.24, representing an increase of 11.37% compared to ¥234,594,741.64 in the same period last year[5] - Net profit attributable to shareholders was ¥6,642,081.65, a significant turnaround from a loss of ¥25,460,550.66 in the previous year, marking a 126.09% improvement[5] - Basic and diluted earnings per share improved to ¥0.01 from a loss of ¥0.05, reflecting a 120.00% increase[5] - Operating profit for the current period was ¥9,366,855.16, a significant recovery from a loss of ¥27,268,564.97 in the previous period[19] - Net profit attributable to the parent company was ¥6,642,081.65, compared to a loss of ¥25,460,550.66 in the previous period, marking a turnaround[20] Cash Flow and Investments - The net cash flow from operating activities decreased by 60.14%, down to ¥10,058,746.76 from ¥25,233,688.30 year-on-year[5] - The company reported a net cash outflow from investing activities of ¥11,349,624.10, an improvement from a net outflow of ¥32,705,291.85 in the previous period[23] - The cash and cash equivalents at the end of the period were ¥343,000,036.81, compared to ¥326,002,953.77 at the end of the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,987,063,157.81, a slight decrease of 0.44% from ¥1,995,807,969.26 at the end of the previous year[5] - Current assets totaled CNY 645,941,574.54, showing a marginal increase from CNY 644,069,184.30[16] - Total liabilities decreased to CNY 742,649,696.89 from CNY 757,745,151.71, reflecting a reduction of about 2%[17] - Non-current liabilities totaled CNY 408,903,156.39, a decrease from CNY 411,047,175.16, indicating a reduction of about 0.3%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,012[11] - The company plans to issue shares to specific targets, pending approval from shareholders and regulatory bodies[14] Operational Efficiency - Total operating costs decreased to ¥260,328,377.29 from ¥263,463,408.41, a decline of 1.6%[19] - Research and development expenses decreased to ¥12,101,507.40 from ¥16,901,112.25, reflecting a 28.5% reduction[19] Other Financial Metrics - The weighted average return on equity increased to 0.55% from -1.79% in the previous year, showing a positive trend[5] - Financial expenses decreased by 50.21%, down to ¥1,121,555.27 from ¥2,252,352.80, primarily due to reduced interest expenses[10] - The company recorded a non-operating income of ¥8,213,051.55, which includes gains from the disposal of non-current assets[7] - The company experienced a foreign exchange loss of ¥272,754.98 in other comprehensive income, contrasting with a gain of ¥1,875,939.70 in the previous period[20] - The company's cash and cash equivalents decreased to CNY 347,919,860.57 from CNY 368,328,773.14[16] - Accounts receivable rose to CNY 202,796,534.68, up from CNY 176,719,261.33, indicating a growth of approximately 14.7%[16] - Inventory increased to CNY 13,596,368.84 from CNY 11,441,020.50, representing a growth of approximately 18.9%[16] - The company reported a net loss of CNY 673,929,631.53 in retained earnings, slightly improved from a loss of CNY 680,571,713.18[18] - The company's equity attributable to shareholders increased to CNY 1,220,230,623.22 from CNY 1,213,861,296.55[18]